Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $57.25.

AGIO has been the topic of several recent research reports. Bank of America dropped their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Zacks Research cut Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. HC Wainwright reiterated a “buy” rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Scotiabank decreased their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research report on Monday, July 28th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $43.24 on Friday. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The stock’s 50-day simple moving average is $39.56 and its 200 day simple moving average is $35.77. The stock has a market capitalization of $2.51 billion, a P/E ratio of -6.18 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 27.50% and a negative net margin of 895.86%.The business’s quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $16.22 earnings per share. Equities research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Theodore James Jr. Washburn sold 8,546 shares of the company’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $36.87, for a total transaction of $315,091.02. Following the sale, the insider directly owned 868 shares in the company, valued at $32,003.16. This represents a 90.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Brian Goff sold 11,085 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $36.67, for a total transaction of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares in the company, valued at approximately $4,529,771.76. This trade represents a 8.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 26,784 shares of company stock valued at $1,009,049. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in AGIO. CWM LLC increased its stake in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 996 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Agios Pharmaceuticals by 28.8% during the first quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 1,964 shares in the last quarter. GW&K Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 19.6% during the first quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock worth $23,954,000 after acquiring an additional 134,063 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $1,601,000. Finally, TD Asset Management Inc raised its stake in shares of Agios Pharmaceuticals by 7.5% during the first quarter. TD Asset Management Inc now owns 178,072 shares of the biopharmaceutical company’s stock worth $5,218,000 after acquiring an additional 12,400 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.